TCT-538 Clinical outcomes following percutaneous coronary intervention with Absorb BVS in patients with distal coronary artery disease. Results from the Italian RAI multicenter registry  by Mojoli, Marco et al.
B220 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5TCT-538
Clinical outcomes following percutaneous coronary intervention with
Absorb BVS in patients with distal coronary artery disease. Results from
the Italian RAI multicenter registry
Marco Mojoli,1 Giuseppe Tarantini,1 Giulia Masiero,1 Attilio Varricchio,2
Alfonso Ielasi,3 Bernardo Cortese,4 Francesco Granata,2
Elisabetta Moscarella,2 Maurizio Tespili,3 Roberto Adriano Latini,4
Paola Tellaroli,5 Donatella Corrado,6 Giuseppe Steffenino7
1Cardiology Clinic, University of Padua, Padova, Italy; 2Department of
Cardiothoracic Science, Second University of Naples, Naples, Italy;
3Azienda Ospedaliera Bolognini, Seriate (BG), Italy; 4A.O.
Fatebenefratelli Milano, Milano, Italy; 5University of Padua Medical
School, Padova, Italy; 6Fondazione Mario Negri Sud, Santa Maria
Imbaro, Italy; 7A.O. S. Croce e Carle, Cuneo, Italy
BACKGROUND The treatment of coronary artery disease involving
distal segments remains a challenge. Differently from metallic plat-
form stents (MPS), bioresorbable vascular scaffolds (BVS) may
potentially provide expansive remodeling, the return of vessel vaso-
motion and permit surgical revascularization. Notwithstanding, data
at late follow-up in this setting are scant.
METHODS The Italian RAI Registry is an ongoing, spontaneous,
multicenter prospective data collection which evaluates all patients
treated at participating centres with the second-generation ever-
olimus-eluting Absorb BVS. Our analysis was restricted to patients
who received Absorb BVS implantation in at least one distal segment
of an epicardial coronary artery.
RESULTS Between March 2012 and June 2015, 1089 consecutive un-
selected patients were treated by BVS. 121 patients (mean age 59
years, 86% males) were included in this analysis. A total of 135 lesions
involving distal segments were treated with Absorb BVS in this cohort.
Seventy-six (63%) patients had an acute coronary syndrome. Diabetic
patients were 29 (24%). Multivessel coronary artery disease was pre-
sent in 69% of patients, and the median SYNTAX score was 17  12.
Multivessel implantation occured in 40 (33%) patients and 21% of
patients received metallic stents proximally. The total number of BVS
implanted was 269, with an average of 2.2/patient. Final scaffold
length was 28 mm in the majority of patients (52%) with 79 overlaps.
Procedural success occurred in 96% of patients. At a median follow up
of 25 months (interquartile range, 12 – 37 months), target lesion failure
rate was 5.8%. More in detail, adverse events were: 1 cardiac death, 5
target vessel myocardial infarctions, 4 target lesion revascularizations
because of deﬁnite scaffold thrombosis (3 sub-acute, 1 very late).
CONCLUSIONS By the data of the RAI registry, the implantation of
Absorb BVS in distal segments is promising. Randomized studies are
needed to assess the potential beneﬁt of BVS to treat distal coronary
lesions compared to MPS or incomplete revascularization.
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BACKGROUND Percutaneous coronary intervention (PCI) with bio-
resorbable vascular scaffold (BVS) placement holds great potential,
but concern has recently been raised regarding the risk of scaffold
thrombosis (ST). The aim of this study was to determine the risk of ST
following PCI with placement of an ABSORB BVS by conducting a
systematic review and meta-analysis.
METHODS Medline/PubMed, Cochrane CENTRAL, and meeting ab-
stracts were searched for all studies that included outcomes data in
patient following PCI with BVS placement. For studies comparing BVS
with drug-eluting stents (DES), pooled estimates of outcomes, pre-
sented as odds ratios (OR) [95% conﬁdence intervals], were generated
with random-effect models.
RESULTS Our analysis included 10,021 patients (8,303 with BVS and
1,718 with DES) with a follow-up of 6.45.1 months, age of 6011, 78%were male, 38% had stable angina, and 56% had ACS. CV death
occurred in 0.6% of patients with BVS, MI in 2.1%, target lesion
revascularization in 2.0%, and deﬁnite/probable ST in 1.2% of pa-
tients. Among BVS patients, 0.3% had acute ST and 0.6% had subacute
ST, yielding a risk of 0.9% for ST in the ﬁrst month. Meta-analysis
demonstrated patients that received BVS were at a higher risk of MI
(OR 2.06[1.26-3.36], p¼0.004) and deﬁnite/probable ST (OR 2.14 [1.02-
4.50], p<0.05) during follow-up (Figure).
CONCLUSIONS Patients undergoing PCI with BVS had increased
deﬁnite/probable ST and MI during follow-up compared with DES.
Measures to minimize scaffold thrombosis are warranted. Further
randomized controlled trials with the long-term follow-up will
determine the overall utility of BVS compared to DES implantation in
high-risk patient subgroups.
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BACKGROUND There is limited data on the impact of postdilation
(PD) on acute procedural and clinical outcomes in patients with long
and complex lesions treated with bioresorbable vascular scaffolds. We
sought to evaluate the effect of PD on procedural and clinical out-
comes in a ‘real world’ population.
METHODS We performed an analysis of patients who underwent BRS
implantation and enrolled into our institutional BVS STEMI FIRST and
EXPAND registries. Pre and post dilation were encouraged with at
least 1:1 preballoon: artery (B: A) and postballoon: scaffold (B: S) ratios
respectively. Baseline clinical and angiographic (including quantita-
tive coronary angiographic analysis; QCA) characteristics were
collected. The effect of PD on angiographic outcome were also eval-
uated using appropriate views taken immediately after BRS implan-
tation (before postdilation) and ﬁnal procedure when available.
Patients were followed up routinely through telephone call and hos-
pital visits. Procedural end points studied included device and pro-
cedure success and complication rates. Major adverse cardiovascular
events (MACE) studied included all-cause mortality, myocardial
infarct, target lesion revascularization and scaffold thrombosis.
RESULTS 294 patients with 387 lesions treated with 529 BRS were
studied of which 164 patients with 211 lesions underwent PD (Post B:S:
